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ABSTRACT 
Genome changes in terms of numerical chromosomal aberrations and structural 
rearrangements, including deletions, amplifications and translocations, gradually 
accumulate in the genome during tumor development. These genomic changes are 
likely to play an important role in the process of tumor progression. A detailed high 
resolution study of genome rearrangements in breast cancer and their relation to tumor 
progression and risk for metastasis was performed. 
A combination of the high resolution arrayCGH (aCGH) technique ROMA 
(Representational Oligonucleotide Microarray Analysis) and the molecular cytogenetic 
technique FISH (Fluorescence In Situ Hybridization) made it possible to identify genes 
and chromosomal regions that display aberrations as gains, losses and rearrangements. 
These chromosomal aberrations were analyzed quantitatively and related to the 
progression of the cancer disease. 
Three characteristic patterns of genomic copy number variations in breast cancer were 
identified, simplex, complex I (“sawtooth”) and complex II (“firestorm”). The simplex 
pattern has broad segments of duplication and deletion, usually comprising entire 
chromosomes or chromosome arms. The “sawtooth” pattern is characterized by many 
narrow segments of duplication and deletion, often alternating, more or less affecting 
all the chromosomes. The “firestorm” pattern resembles the simplex type except that 
the cancers contain at least one localized region of clustered, relatively narrow peaks of 
amplification, with each cluster limited to a single chromosome arm. The simplex 
pattern is associated with low malignant tumors whereas the complex patterns are 
associated with high malignant tumors. M-FISH enabled us to study the spatial 
organization between different chromosomal regions in the cell nucleus and validate 
the observed gene copy number changes quantitatively. 
A method, named Sector-Ploidy-Profiling (SPP), was developed and used to compare 
different subpopulations from different areas in a tumor. Clonal genomic heterogeneity 
was found to be very common in breast cancers. The clonal subpopulations were found 
to be either anatomically separated or intermixed. By comparing the different 
subpopulations, a better understanding of the order of genomic events during tumor 
development could be obtained. 
Inspired by the simplex and complex patterns we developed an objective estimate of 
genomic alterations in aCGH data. By using this method a clear relationship between 
genomic alterations (copy number changes and structural rearrangements) and gene 
expression subtypes was found. 
By combining ROMA with M-FISH it became possible to study specific translocations 
in interphase chromatin in clinical samples. The specific translocation between 
chromosome 1 and chromosome 16, t(1;16), could now be visualized in both invasive 
breast carcinoma and in ductal carcinoma in situ (DCIS), indicating that the 
translocation t(1;16) is an early event during breast cancer development. In DCIS 
however, cells with and without translocations were found to co-exist in the same area 
of the tumor. This suggests that intraductal proliferation leading to DCIS precedes the 
translocation t(1;16). 
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1 INTRODUCTION 
Cancer is a genetic disease that develops from single cells that acquire mutations in the 
genome as the cells evolve from normal to malignant (Vogelstein and Kinzler 1993). 
Mutations can be a single nucleotide change, deletion or duplication of a DNA 
sequence (Wiedemann and Morgan 1992). Cancer represents a spectrum of biologically 
different diversities and can occur in most organs of the human body. Each cancer is 
unique with its own genetic defects. However, the characteristic phenotypes of cancer 
cells are similar; The hallmarks of cancer cell (Hanahan and Weinberg 2000) is self-
sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, 
limitless potential for replication, sustained angiogenesis and tissue invasion and 
metastasis. Each one of these hallmarks will be briefly discussed below. 
Self-sufficiency in growth signals. To initiate cell division, normal cells require 
mitogenic signals from the surrounding environment to divide and proliferate. Cancer 
cells, on the other hand, often produce their own growth signals and can proceed 
through the different cell cycle phases and divide without signals from its surroundings. 
Insensitivity to antigrowth signals. Normal cells can arrest and differentiate in 
response to antiproliferative signals. Cancer cells on the other hand, are often 
insensitive to these antimitogenic signals and continue to proliferate unchecked 
Evading apoptosis. Many pathways and signals, such as DNA damage, can activate 
the cellular suicide program. When the cell receives a cell death signal, it undergoes 
organized degradation of its cellular organelles following activation of proteolytic 
enzymes, known as caspases. Caspase activation leads to DNA fragmentation, 
shrinking of the cell membrane and eventually neighboring cells consume the cellular 
remains. Tumor cells avoid apoptosis even when the damaged DNA has not been 
repaired, which can result in genomic instability. 
Limitless potential for replication. Normal cells undergo a limited number of cell 
divisions and then lose their ability to divide. However, tumor cells can replicate an 
infinite number of times. The process of aging is complex and how it is regulated is not 
exactly understood. Normally telomeres get shorter with every round of DNA 
replication but tumor cells can avoid this by, for example, activating a mechanism that 
maintains telomere length. One way to do this is by activation of telomerase (Greider 
and Blackburn 1985). 
Sustained angiogenesis. In normal tissues the growth of new blood vessels is transient 
and tightly regulated. Cancer cells, however, induce and sustain blood vessel growth. A 
fundamental step of malignant progression is that the tumor expands and grows beyond 
a certain size. For this to happen, the cancer cells in the tumor secrete signals that 
stimulate formation of new blood vessels to support its growth. 
Tissue invasion and metastasis. Normal cells do not have the ability to grow and 
survive outside their own niche. Cancer cells, on the other hand, have the potential to 
invade surrounding tissue and metastasize to distant locations. A whole series of 
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controls that normally keep cells in its true environment is altered when cancer cells 
escape from its originating tissue including the degradation of proteins that make up the 
surrounding extracellular matrix (ECM). When tumor cells metastasize, they are called 
secondary tumors, as compared to the primary tumor where the cancer originated from.  
Acquisition or elimination of the individual properties mentioned above is enabled by 
mutations in genes regulating cellular homeostasis and DNA. These genes can be 
categorized into two gene groups that are responsible for tumorgenesis: oncogenes and 
tumor suppressor genes (TSG). Properties of these groups of genes will be discussed 
below. 
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2 BREAST CANCER 
Breast cancer, is, like most other cancer types, a heterogeneous disease with respect to 
its clinical and biological behavior (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001). 
Breast cancer is the most common cancer disease among women in the western world. 
In Sweden 7049 women and 39 men were diagnosed with the disease. The relative 
survival rate of the disease five years after diagnosis is about 90 percent, and after 10 
years the corresponding number is 80 percent (Cancer Incidence in Sweden 2008 
2009). The majority of breast cancers are sporadic, but there is a small group that is 
attributed to known hereditary factors. Two genes involved are BRCA1 and BRCA2. 
With mutations in these genes the risk of breast cancer is highly increased (Edlich, 
Winters et al. 2005).  
Breast cancer classification includes histopathological type, stage, grade and receptor 
status and are described below. 
2.1 HISTOPATHOLOGICAL TYPE 
The main tissue of the breast are the mammary glands. Each mammary gland consists 
of multiple lobules connected to ducts and surrounding tissue, and includes blood 
vessels. Malignant breast tumors usually arise from one of the above mentioned 
structures. Ductal carcinomas are most common (75-80% of cases), followed by lobular 
carcinomas (10-15% of cases). Malignancies arising from other connective tissues of 
the breast are not as common.  
2.2 STAGING 
Tumor stage is a clinical evaluation of how far the disease has progressed at the time of 
diagnosis. In Sweden the TNM (Tumor, Node and Metastasis) classification is used for 
classifying the extent of cancer spread. TNM is based on primary tumor size, presence 
and distribution of regional lymph nodes and distant metastases. 
2.3 GRADING 
Grading of the disease is a microscopic estimation of the morphological abnormality 
and is an indicator of prognosis in breast cancer. Invasive breast carcinoma is 
histologically graded (grade 1-3) using the Elston-Ellis system, which is based on the 
status of tubule/gland formation, nuclear pleomorphism and mitotic count (Elston and 
Ellis 1991) (Elston and Ellis 2002). Each of these characteristics is scored from 1 to 3 
and the scores are then summarized resulting in a value between 3 and 9. The grade is 
then assigned as follows: Grade 1 (3-5p) – well differentiated, Grade 2 (6-7p) – 
moderately differentially and Grade 3 (8-9p) – poorly differentiated. 
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2.4 RECEPTOR STATUS AND PROLIFERATION MARKERS 
Hormone receptor status and proliferation markers of the breast tumor are also tested. 
These include the status of Estrogen (ER) and Progesterone receptors (PgR). Each of 
these receptor statuses are scored as either positive or negative. Cancers that are 
hormone-receptor-positive (ER+/PgR+) usually grow slowly, and have a much better 
chance of responding to hormone-suppression treatment than cancers that are hormone 
receptor negative (ER-/PgR-) (Key and Pike 1988). Another marker assessed is HER2-
receptor status, since it effects the treatment the patient will receive. HER2 positive 
breast cancers are, for example treated with Herceptin which is a drug that targets the 
HER2-receptor protein on the cell surface (Albanell and Baselga 1999). Proliferation 
markers, such as Ki67 and Cyklin A, may also be used as prognostic factors. 
In 2000, Sørlie and Perou et al. proposed that breast cancer could be divided into 
subsets that have different clinical outcome. The subsets are based on expression of a 
few hundred mRNA transcripts. Five molecular subtypes have been identified: basal 
like, normal like, HER2, Luminal A and Luminal B. The subgroups differ in clinical 
characteristics and prognosis. Luminal A has a good prognosis and Luminal B, also 
described as triple negative (ER-, pGR- and HER2-) has an unfavorable prognosis 
(Perou, Sorlie et al. 2000) (Sorlie, Perou et al. 2001). These patterns are further 
compared with the genomic pattern in Paper III. 
2.5 TREATMENT 
Breast cancer is usually treated by surgical removal of the primary tumor with breast-
conserving surgery (partial mastectomy, segmental resection or lumpectomy) or 
removal of the whole breast (mastectomy) and axillary lymph node sampling, e.g. 
sentinel node procedure. Information about lymph node status has great impact on the 
decision of further treatment. Breast-conserving surgery is usually followed by 
radiotherapy. Adjuvant therapy includes chemotherapy, endocrine therapy and/or 
biological target therapies. Choice of therapy is based on staging, grading and receptor 
status. 
 5 
 
3 CANCER GENOMICS 
As mentioned above, mutations of two major types of genes are involved in the 
development of cancer. Some of these genes are positive regulators of cancer growth, 
oncogenes, and some are negative regulators of cancer growth, tumor suppressor genes 
(TSG). 
3.1 ONCOGENES 
The first indication of the existence of oncogenes was done by Peyton Rous, as he 
identified a retrovirus that caused tumor formation in chicken (Rous 1911). Michael 
Bishop and Harold Varmus later showed that oncogenes in retroviruses have a cellular 
origin, and this led to the idea that oncogenes represent incorrectly activated normal 
genes (Stehelin, Varmus et al. 1976). An oncogene is a mutated form of a proto-
oncogene, a gene that normally drives cell division in a controlled manner when it is 
required (Todd and Wong 1999). 
Oncogene activation can result from chromosomal translocations, gene amplifications 
or mutations leading to deregulation of the of the gene product (Vogelstein and Kinzler 
2004). An example of an oncogene in breast cancer is erbB2 which is amplified and 
overexpressed in about 20% of primary breast cancers. Overexpression of the 
corresponding protein HER2, leads to aberrant cell growth regulation (Lane, Beuvink et 
al. 2000). Other common oncogenes are CCND1, c-MYC and Ras (Rat sarcoma) 
(Osborne, Wilson et al. 2004). 
3.2 TUMOR-SUPRESSOR GENES 
The tumor suppressors are in involved in the control of cell division and thereby have 
capacity to prevent tumor formation. Alfred Knudsen formulated a “two hit hypothesis” 
in 1971 (Knudson 1971) which states that both copies (maternal and paternal) of the 
particular TSG must be inactivated before any effect can be seen. As long as one allele 
is intact it can usually compensate for the loss of the other. Loss of function of both 
gene copies commonly arises through a loss of an entire chromosome or chromosome 
arm, coupled with a mutation of the other allele. Mutations that inactivate TSGs are 
deletions, point mutations and epigenetic silencing (Knudson 2002).  
Tumor suppressor genes are involved in many pathways such as apoptosis, negative 
cell cycle control and DNA repair and can be divided into two major groups i.e. 
“gatekeepers” and “caretakers” (Kinzler and Vogelstein 1998). The “gatekeepers” 
includes all direct inhibitors of cell growth. The “caretakers” are genes that indirectly 
suppress tumor development by being involved in DNA repair and prevention of 
genomic instability. One of the most studied tumor suppressor gene is p53, which has 
been referred to as “the guardian of the genome” (Lane 1992) because of its importance 
in cancer protection. This is achieved by inducing cell cycle arrest and/or apoptosis as a 
response to, for example DNA damage or oncogene activation (Levine 1997). 
Mutations of p53 are estimated to occur in 20-30% of the breast cancers (Hollstein, 
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Sidransky et al. 1991). Other identified TSG in breast cancer are the Retinoblastoma 
gene (RB), BRCA1 and BRCA2 (Macleod 2000).  
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4 CHROMOSOMAL ABERRATIONS 
Already in 1914 Theodore Boveri suggested that cancer might result from a disturbance 
in the chromosome balance (Holland and Cleveland 2009). This was only a theory until 
1960 when the Philadelphia chromosome, identified as a minute chromosome, was 
discovered in patients with leukemia (Nowell 1962). The Philadelphia chromosome 
was later identified as a translocation between chromosome 9 and chromosome 22 
(Rowley 1973). 
Chromosomal aberrations can involve numerical chromosomal changes and/or 
structural chromosomal changes including deletions, amplifications and translocations. 
Numerical chromosomal abnormalities is a condition known as aneuploidy. 
Aneuploidy is a defect in chromosome number as a result of miss-segregation of 
chromosomes during cell division (Lengauer, Kinzler et al. 1997; Thompson and 
Compton 2008). Human tumors can be divided into two groups, A-tumors and D-
tumors, based on their gross ploidy level as judged from their nuclear DNA content. A-
tumors represent highly aneuploid tumors and D-tumors represent diploid or near-
diploid tumors. It was shown in 1970s and early 1980s that A-tumors are associated 
with bad prognosis (Atkin 1972; Eneroth and Zetterberg 1975; Eneroth and Zetterberg 
1976; Zetterberg and Esposti 1976; Auer, Caspersson et al. 1980). 
Furthermore, it has been shown that A-tumors, besides from being aneuploidy, also are 
associated with regional structural changes on several chromosomal locations. Most D-
tumors on the other hand, have fewer structural changes usually consisting of gain or 
loss of whole chromosome arms (Ried, Just et al. 1995). We performed a high 
resolution analysis of structural chromosomal rearrangements and its relation to gross 
ploidy level (A-type or D-type) in 2005 (Hicks, Muthuswamy et al. 2005). It was found 
that a small proportion of the D-tumors that metastasis early showed a high degree of 
rearrangements similar to that of A-tumors. These results were extended and related to 
survival data showing a clear association between number and type of structural 
chromosomal rearrangements and prognosis as described in detail in paper I. 
Acquired knowledge of chromosome aberrations increases our understanding of the 
evolutionary pathways and factors that are important in the initiation, development and 
progression of cancer. Comparing aberrations in different tumors and assuming that 
mutations accumulate as the tumor progresses is one way to infer tumor progression. 
An alternative, and more direct approach, to study tumor progression is to compare 
multiple samples taken from different parts of a tumor, (See paper II) 
Frequently observed genomic alterations in breast carcinomas include gain of 1q, 8q, 
16p,17q and 20p, loss of 16q and 17p and amplification in 8q12-24, 11q11-13, 17q12-
21, 17q22-24 and 20q13-ter reviewed in (Reis-Filho, Simpson et al. 2005) 
4.1 DELETIONS/DUPLICATIONS 
One common abnormality in cancer cells is gain or loss of whole chromosomes or 
chromosome arms or segments. The fundamental consequence of this is difficult to 
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establish because the gain/loss extends tens or thousands of mega bases and affect 
segments that contain hundreds of genes.  
Deletions can be seen as 3 different types: (i) whole arm deletions, (ii) segmental 
deletions of partial chromosome arms or (iii) small regional deletions adjacent, and 
possible associated, to amplifications. These types are described in detail in paper I, III 
and IV (see further below). 
The most frequent event in breast cancer tumors with few chromosomal alterations 
involves gain of the long arm of chromosome 1 (1q) and loss of the long arm of 
chromosome 16 (16q). In breast cancer loss of 16q is associated with lower grade 
tumors that do not metastasize (Buerger, Otterbach et al. 1999).  
4.2 GENE AMPLIFICATIONS 
Gene amplification means an increase of the number of genes or several genes in a 
chromosomal region. This phenomenon was first described by Schimke et al. 
(Schimke, Alt et al. 1978; Schimke, Sherwood et al. 1986). N-myc was the first gene 
described as amplified in tumor material (Kohl, Kanda et al. 1983; Schwab, Alitalo et 
al. 1983). Amplifications are the most studied chromosomal aberration in breast cancer 
(Santarius, Shipley et al. 2010) (Albertson 2006) and gene amplification is an important 
mechanism for oncogene overexpression in malignant tumors including breast cancer. 
Amplifications involving chromosomes 11q13.3 (CCND1) and 17q12 (ERBB2) are 
among the most common high level copy number aberrations in breast tumors (Bates 
and Peters 1995) (Slamon, Clark et al. 1987; Latham, Zhang et al. 2001) (Letessier et 
al., 2006). 
Gene amplifications seem to be initiated by DNA double-strand break, and only occur 
in cells which are not able to detect DNA damage (Albertson 2006). There have been 
several suggestions as to what could promote amplifications, including error during 
DNA replication, telomere dysfunction and fragile sites, i.e. sites associated with an 
increase in chromosome instability. Studying amplifications in cell lines and tumors 
have revealed that amplifications can be organized in different ways: (i) as double 
minutes, which is extrachomosomal copies, (ii) in tandem arrays, which is series of 
copies of a gene arranged in tandem along a chromosome and (iii) within a 
chromosome or distributed at various locations throughout the genome (Albertson, 
Collins et al. 2003). The size of an amplicon can varies from kilobases to tens of 
megabases (Albertson 2006). 
4.3 CHROMOSOME TRANSLOCATIONS IN BREAST CANCER 
Chromosomal rearrangement in terms of translocations is a common property of 
malignant cells (Mitelman 2000). A translocation is a type of chromosomal 
rearrangement in which a chromosome breaks and a portion of it reattaches to a 
different chromosome. The translocation can be either reciprocal, which means that two 
chromosomes swap portions of arm with each other resulting in two translocation 
products, or non-reciprocal where one of the translocation products is lost (resulting in 
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only one translocation product) (Ferguson and Alt 2001). In balanced translocations, 
exchange of chromosomal material does not result in loss or gain of genetic 
information, in contrast, unbalanced translocations can result in both gain and loss of 
genetic material. 
Balanced translocations can dysregulate critical cancer genes in different ways. A 
translocation can rearrange a gene to chromosomal regulatory regions that cause the 
gene to be deregulated (Look 1997). Translocations can also result in fusion of two 
separate genes resulting in a chimeric oncoprotein with transforming abilities (Rabbitts 
1994). For example, hematological malignancies often display single balanced 
translocations, whereas the study of translocations in epithelial cancers has been limited 
mostly because of technical limitations in cytogenetics (Mitelman, 2000). For a long 
time it was thought that translocations in common epithelial cancers were unbalanced 
and that the consequence of that was mainly loss of a loss of tumor suppressor genes. 
(Dutrillaux 1995). Recent technical advances made it possible to search for fusion 
genes, findings in the past few years show that gene fusions caused by balanced 
translocations indeed exists in these cancer forms, and may play an important role in 
common epithelial cancers such as breast cancer (Edwards 2010). 
Translocation studies on established breast cancer cell lines and cells from tumor 
samples indicated that chromosomes 1, 8, 16, 17 and 20 are most frequently involved in 
chromosome translocations of breast cancer (Dutrillaux, Gerbault-Seureau et al. 1990; 
Kokalj-Vokac, Alemeida et al. 1993; Tsuda, Takarabe et al. 1997; Kytola, 
Rummukainen et al. 2000). These chromosomes are often involved in rearrangements 
as gains and losses in the breast cancer genome (Ried, Just et al. 1995) (Jonsson, Staaf 
et al. 2010). 
Loss of 16q is frequently found in breast tumors. In some tumors the loss of 16q takes 
place simultaneously with a gain of 16p. Gains and losses on chromosome 16 seem to 
occur at a very high frequency in tumors that also have a gain of 1q. Our study in paper 
number IV is based on the assumption that this gain on 1q together with a simultaneous 
loss of 16q might reflect a previously described chromosome translocation (Flagiello et 
al., 1998; Kokalj-Vokac et al., 1993; Pandis et al., 1992; Tsuda et al., 1997). 
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5 CYTOGENETIC AND MOLECULAR METHODS USED 
TO DETECT CHROMOSOMAL ABERRATIONS 
Cytogenetics refers to the study of the chromosomes, description of their structure and 
identification of chromosomal aberrations. In 1970 Casperson et al. (Caspersson, Zech 
et al. 1970) invented the chromosome banding technique which made it possible to 
produce a visible karyotype by staining condensed chromosomes of metaphase plates 
with the fluorescent agent quinacrine. Later Giemsa banding was later introduced as an 
alternative technique (Evans, Buckton et al. 1971). This technique is still used to 
identify chromosomal aberrations, such as translocations. 
5.1 CHROMOSOME NOMENCLATURE 
In Paris in 1971 a group of 50 scientists engaged in cytogenetic diseases formulated a 
system of nomenclature for individual chromosome bands (Paris Nomenclature 1973). 
A short summary of the system is presented here: 
Each chromosome consists of two arms, uneven in length, separated by the centromere. 
The short arm is labeled p (for petit) and the long q (for queue). On each chromosome 
arm regions and bands are numbered sequentially from the centromere and out on each 
arm. To describe a specific chromosomal region on an individual band the chromosome 
number, arm symbol, region number and band number are listed in order without space 
or punctuation. For example 11q13 is the long arm of 11, region 1 and band 3. To 
describe a sub-band a decimal is placed after the band followed by the sub-band 
number, for example 11q13.3 (Figure 1). 
 
Figure 1. Schematic representation of chromosome 11.  
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5.2 METAPHASE SPREAD ANALYSIS 
Advances in the metaphase spread analysis with the introduction of fluorescence in situ 
hybridization (FISH) methods using combinatorial labeling or ratio labeling techniques 
made it possible to study structural chromosomal aberrations and complex 
chromosomal rearrangements in a more detailed manner. These techniques made it 
possible to simultaneously visualize all 24 chromosomes in different colors in one 
experiment. Technologies that used this techniques are multi-color FISH (M-FISH) 
(Speicher, Gwyn Ballard et al. 1996), spectral karyotyping (SKY)(Schrock, du Manoir 
et al. 1996) and combined binary ratio labeling (COBRA)(Tanke, Wiegant et al. 1999). 
5.3 COMPARATIVE GENOMIC HYBRIDIZATION (CGH). 
One problem in using banding technique and spectral karyotyping is the need of 
metaphase spreads, which is especially problematic when analyzing solid tumors. To 
overcome this problem, Kallioniemi et al.(Kallioniemi, Kallioniemi et al. 1992) 
developed a new method, comparative genomic hybridization (CGH). CGH provides 
an overview of the aberrations across the genome, with the restriction that it is only 
sensitive to changes in the genomic content and cannot detect balanced translocations 
(Albertson, Collins et al. 2003). The principle of CGH is simple, tumor DNA and 
reference DNA are labeled differentially – for example, with the tumor DNA labeled 
with green fluorescent dye and normal DNA with red fluorescent dye. The labeled 
DNA is then mixed in a 1:1 ratio. The combined probes are then applied on metaphase 
chromosomes were they will compete for complementary hybridization sites. A 
fluorescence microscope is used to capture images of the chromosomes. If a region in 
the tumor DNA is amplified, the corresponding region on the metaphase chromosome 
will display more green dye and if a region is lost the corresponding region will appear 
redder. The ratios of tumor and normal are calculated by special image analysis 
software. 
5.4 ARRAY CGH 
The sensitivity and resolution of the CGH technique was further improved by the 
development of array CGH (aCGH). aCGH made it possible to identify chromosomal 
aberrations that were not previously detectable. The principles of aCGH are similar to 
those of CGH, but instead of having metaphase chromosome as a target, the platform is 
composed of a large number of mapped clones (for example bacterial artificial 
chromosomes [BAC] covering regions of interest) on a microarray. The resolution of 
the analysis is therefore limited to the clone size and space between the clones. The first 
platforms had large clones, such as BACs, as targets (Solinas-Toldo, Lampel et al. 
1997) (Pinkel, Segraves et al. 1998). However, the use of oligonucleotide arrays 
increased the resolution even more additionally. To reduce probe complexity, and to 
optimize for fragments of a specific size, oligonucleotide arrays can use 
“representations” of the genome instead of using genomic DNA (Lucito, Healy et al. 
2003). This will be elaborated on further under the part describing Representational 
Oligonucleotide Microarray Analysis (ROMA). 
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Array CGH is an excellent method for identifying copy number alterations and 
chromosomal breakpoints in unbalanced rearrangements, but cannot identify balanced 
rearrangements such as reciprocal translocations (Davies, Wilson et al. 2005).  
5.5 INTERPHASE FISH 
Interphase Fluorescence In Situ Hybridization (FISH) makes it possible to study the 3D 
organization of the genome. Structural rearrangements such as translocations have been 
visualized with FISH (Arnoldus, Wiegant et al. 1990; Tkachuk, Westbrook et al. 1990). 
Another advantage with interphase FISH is the possibility to study the distribution of 
cells in a sample when looking for different clones in a tumor population. 
5.6 NEXT GENERATION SEQUENCING 
During the last few years advances in technology for high-throughput, massively 
parallel sequencing (next generation sequencing) has made it possible to allow 
sequencing at single nucleotide resolution of the entire genome at a relatively low cost 
(Reis-Filho 2009). This technique has already been used in identifying somatic 
rearrangements in breast cancer (Stephens, McBride et al. 2009), and will probably be 
the main technique to study chromosomal rearrangements in the future. 
5.7 ROMA - REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS  
Representational Oligonucleotide Microarray Analysis (ROMA) was developed at Cold 
Spring Harbor laboratories (CSHL) (Lucito, Healy et al. 2003). ROMA is an array 
based hybridization method that uses genomic complexity reduction based 
representations, which in a single experiment can report genome wide copy number 
changes at a resolution of 30kb (kilo base pairs). 
In the material presented in this thesis we performed comparative hybridization using 
Bgl-II representations (as described below), and arrays of 85 000 oligonucleotide (50 
mer) probes with a mean interprobe distance of 35 kb. Differences in gene copy 
number between two genomes, for example normal DNA and tumor DNA, were 
compared on a microarray. The genome was digested with a restriction enzyme (Bgl-II, 
an enzyme with a typical 6-bp recognition site), ligated with adapters specific to the 
restriction fragment sticky ends and amplified by PCR. The representations of the 
different genomes were labeled with different fluorophores and hybridized to a 
microarray with probes specific to locations spread throughout the genome (Figure 2).  
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Figure 2. Representational Oligonucleotide Microarray Analysis (ROMA). (This figure is reproduced 
with the permission from Nicholas Navin) 
Each experiment was performed twice with color reversal, and data was rendered as 
normalized ratios of probe hybridization intensity of test to normal. Each raw ROMA 
profile was segmented as described in Hicks et al. 2005 (Hicks, Muthuswamy et al. 
2005) 
Rare copy number variants (CNVs) and more prevalent copy number polymorphisms 
(CNPs) will be present in any high-resolution copy number scan, when comparing one 
person to another due to individual differences in genome content (Sebat, Lakshmi et 
al. 2004). A tumor profile is obtained by comparison to a standard normal male. 
Therefore normally occurring CNPs and CNVs are masked so the analysis does not 
mistake either for a cancer lesion. Figure 3 shows a typical raw ROMA profile and 
segmented profile. Ratios above 1 are considered as a gain and below 1 as a loss. 
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Figure 3. Raw ROMA-profile in blue and segmented ROMA-profile in red. Copy-number ratio is 
graphed on the y axis. Chromosomes 1-22 plus X and Y are displayed in order from left to right 
according to probe position on the x axis. 
5.8 FLUORESCENCE IN SITU HYBRIDIZATION - FISH 
Fluorescence In Situ Hybridization (FISH) is a cytogenetic method which, when it was 
introduced 25 years ago (Pinkel, Gray et al. 1986), opened new opportunities in the 
way chromosome structures could be studied. FISH is a useful tool for locating DNA 
sequences on fixed chromosomes or interphase nuclei. It is a very straightforward 
technique that consists of heat denaturation of the target DNA chromatin and 
hybridization of a fluorescently labeled DNA probe to its complementary sequence. 
Probes are generally labeled by nick translation (Rigby, Dieckmann et al. 1977) 
(Langer, Waldrop et al. 1981) either indirectly with a hapten, a molecule that can bind 
antibodies, or directly via the incorporation of nucleotides that has been modified to 
contain a fluorophore. The target is then visualized in a fluorescence microscope.  
To locate a unique sequence, the probe must cover a chromosomal region large enough 
to give a detectable signal. A problem with this technique is that each probe will 
contain small or large portions of dispersed repetitive DNA sequences. During the 
hybridization process those sequences will anneal to complementary genomic DNAs 
distributed throughout the genome. This results in a background that can have almost 
the same intensity as the target genomic locus. In 1987 Landegent et al. (Landegent, 
Jansen in de Wal et al. 1987) presented a solution to this problem by efficiently 
reducing the background fluorescence by suppressing the nonspecific hybridization of 
probes derived from BAC clones by blocking it by Cot DNA, which contain DNA 
fragments that are 50 to 300 bp (base pairs) in size and is enriched for repetitive DNA 
sequences. Figure 4 shows an example of the influence cot DNA has on an FISH 
image. 
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Figure 4. FISH performed on HDF cells with and without the presence of cot-DNA. BAC clones from 
several chromosomal areas were labeled with a green fluorescent dye. In the left image FISH was 
performed without cot and as one can see the nuclear background level is high. In the right image FISH 
was performed with cot DNA, and one can clearly see that the background has decreased, rendering a 
better signal to noise value. Both images were acquired with the same acquisition time. And the display 
settings for the images are the same. 
Another approach to reduce background is to generate highly specific PCR probes that 
cover a region of a chromosome without any repetitive genomic sequences (Navin, 
Grubor et al. 2006). An example of a FISH showing an amplification of BAG4 and 
deletion of DBC1 can be seen in figure 5. 
 
Figure 5. A FISH example. Amplification of BAG4 and deletion DBC1 
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5.9 ROMA COMBINED WITH FISH 
Both FISH and ROMA are high resolution cytogenetic techniques that can detect small 
deletions, duplications and amplifications in the DNA of tissue samples. When 
studying chromosomal aberrations in tumors, ROMA and FISH techniques 
complement each other. Interphase FISH can reveal the number of specific 
chromosomal regions in each individual cell, and can therefore identify presence or 
absence of different subclones within a tumor sample. A limitation of FISH is that the 
genes or chromosomal regions of interest have to be known to generate specific probes. 
ROMA, on the other hand, can be used to identify chromosomal regions that contain 
copy number changes and/or chromosomal breaks involved in suspected translocations 
without any prior knowledge of the chromosomal regions involved. Information 
rendered from the ROMA profiles enables generation of FISH probes for further 
analysis on cell to cell basis. ROMA gives an average value of the tumor DNA and will 
not reflect clonal variability in a tumor. In paper II of this thesis this particular problem 
is addressed. 
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6 FLUORESCENCE MICROSCOPY 
Fluorescence Microscopy is a powerful tool to study intracellular structures and 
dynamic processes with a high degree of accuracy. It is an essential technique in basic 
research when studying chromosome abnormalities, structure and behavior. 
The basic function of a fluorescence microscope is to illuminate a fluorescent specimen 
with a specific wavelength and to separate the emitted light, which will be of a longer 
wavelength, from the excitation light. The resulting image should be generated only by 
the emitted light, which reaches the eye or the detector.  
6.1 FLUORESCENCE 
Fluorescent molecules absorb light at one wavelength and emit light at another, longer 
wavelength. It is the result of a three stage process that occurs in certain molecules 
called fluorophores or fluorescent dyes. 
First a fluorescent molecule absorbs a photon of a specific energy, which causes the 
molecule to enter an excited state that exists for a finite time (1-10 nanoseconds). 
Thereafter a photon, with longer wavelength than the absorbed photon, is emitted. The 
difference between exciting and emitted wavelengths, known as Stokes shift (Lakowicz 
2006), is a critical property in fluorescence microscopy. The process responsible for 
this can be explained by using a Jablonski diagram, see figure 6. Fluorescent molecules 
are normally found in their ground state (S0 in figure 6). The molecules can absorb 
energy from a photon by changing its vibrational state. If the absorbed energy is large 
enough and if it fits the energy gap of the fluorophore, an electron can move to an 
orbital of higher energy (S1 or S2 in figure 6). The transition to this excited state 
happens on a timescale in the order of femtoseconds. After that, the molecule loses 
energy by undergoing vibrational relaxation so that the electron ends up in the lowest 
level of the first excited state (S1 in figure 6). This process occurs on a timescale of 
picoseconds. From this state, the molecule can return to the ground state through the 
emission of a photon of lower energy and therefore longer wavelength than the exciting 
photon. This phenomenon is referred to as fluorescence. 
Fluorescence emission is not the only way for a fluorophore in its excited state to lose 
its excess energy. Another pathway of energy loss occurs after intersystem crossing 
where the excited molecule ends up in a long lived triplet state. From this state the 
molecule can go to ground state without emission or by a light emission termed 
phosphorescence. The triplet-state molecules can also undergo photochemical reactions 
that can cause permanent bleaching which cause problems. [methods in cell biology vol 
81] 
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Figure 6. A Jablonski diagram. 
6.1.1 Quantum Yield and fluorescence intensity. 
The number of emitted photons that reach the detector is often very low in comparison 
to the number of exciting photons, giving an image that is not as bright as desired. This 
problem consists of several parts. The first part is related to quantum yield, which is 
defined as the ratio between the number of photons emitted and the number of photons 
absorbed. The quantum yield is an inherent property of a fluorophore. Generally the 
number of photons absorbed is greater than the number emitted resulting in a quantum 
yield below one. To maximize intensity of fluorescence it is important to choose a 
fluorophore with high quantum yield. The second part of this problem has to do with 
the fact that the fluorescent light is emitted in all directions, and only a small part 
emitted in the correct direction reaches the objective. A third part is due to the light 
having to pass through a setup of filters, which reduces light intensity. In order to 
maximize the number of photons reaching the detector, high energy mercury lamps are 
usually used to maximize the number of photons exciting the fluorophore. 
A limited problem in fluorescence microscopy is photo bleaching or fading. Fading 
occurs when the fluorescent probes lose their ability to fluoresce. The number of 
fluorescence cycles a fluorophore can fluoresce is limited dependent on the molecule 
and the environment (Lakowicz 2006). 
6.2 THE FLUORESCENCE MICROSCOPE 
Figure 7 shows a schematic image of a fluorescence microscope. Fluorescent molecules 
in the stained sample absorb light of a certain wavelength and emit light of a longer 
wavelength. The dichroic mirror acts as a cut off and reflects light below a given 
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wavelength, while transmitting light of longer wavelengths. The transmitted light is 
then detected by the eye, a detector or a camera. 
 
Figure 7. Schematic image over a fluorescence microscope. 
6.2.1 Objectives 
In fluorescence microscopy the objective is both a source of light to the specimen and 
the collector of emitted light and therefore it has large impact in the resulting image. To 
choose the correct objective is very important to get images as good as possible. The 
magnification of the objective used is important but even more important is the 
numerical aperture (N.A.) that determines the resolution of the lens. The magnification 
is only used to increase the apparent size of an object, whereas increased N.A. 
improves resolution. The numerical aperture (N.A.) of an objective is defined as  
 
              
 
Where   is the refractive index of the medium between the front lens and the specimen 
and      is the half angular aperture of the objective. A high N.A. means that the 
objective collects more light and is also related to the resolution of the objective. The 
resolution of an optical microscope is defined as the shortest distance between two 
points on a specimen that can still be distinguished by the observer or camera system as 
separate objects. Using Rayleigh criterion the minimum resolved distance in the 
microscope specimen, D, is given by 
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Many objectives used today are of immersion type, meaning that the medium between 
lens and specimen is filled with a fluid (oil or water) having a refractive index,   > 1. 
This will increase N.A., and therefore improve the resolution. 
The resolving power of a microscope is the most important feature of the optical system 
and impacts the ability to discriminate between fine details of a specific specimen. 
Modern objectives have a complex lens system composed of numerous internal glass 
lens elements. This gives the objective the best possible performance for its application 
(Abramowitz, Spring et al. 2002). 
6.2.2 Filter 
The primary filter element in most fluorescence microscopes is a set of three filters 
housed in a filter cube: the excitation filter, emission filter and dichroic beamsplitter. 
The excitation filter should only transmit light that excites the fluorophore of interest, 
and these filters are usually of a bandpass type. The emission filter or barrier filter have 
to attenuate all light transmitted by the excitation filter but transmit the emitted light. 
The emission filter can be a bandpass filter or a longpass filter depending on the set up. 
The dichroic beamsplitter is a mirror placed 45 degrees to the optical path of the 
microscope. This mirror has the unique ability to reflect one wavelength (the exciting 
light) but transmit another (the emitted fluorescence). By completely filtering out the 
excitation light, but letting the emitted fluorescence through, it is possible to see only 
the objects that are fluorescent and are of interest. 
In the beginning fluorescence filters were made of colored glass, also called absorption 
glass. Nowadays, interference filters are used for exciter filters to pass the correct 
wavelengths of light with great selectivity and high transmission. Dichroic beam 
splitters are specialized interference filters. Barrier filters may be either made of 
colored glass or interference filters.  
6.2.2.1 Filter design 
When designing a filter the most important parameter is the spectral characteristic of 
the dye. If this were the only parameter to be considered, one would illuminate the 
specimen using a shortpass excitation filter and observe the fluorescence using a 
longpass emission filter that transmits the entire emission spectrum filter. Pathological 
specimens, such as paraffin embedded tissue sections, however, have some 
autofluorescence. Furthermore, light of shorter wavelength such as UV light might 
increase the rate of photobleaching of the fluorophore. Therefore it is better to limit the 
band to a region where the fluorophores excitation is at its maximum, but that is still 
broad enough to get a bright signal. If a second fluorophore is introduced, spectrally 
close to the first there is a risk to detect some emitted light of that fluorophore, often 
referred to as cross-talk or bleed through. This is an undesirable effect and in this case a 
narrower bandpass filter should be used on the emission side. In many applications high 
numbers of fluorochromes are used, and filters with as narrow bands as possible have 
to be selected. The problem with narrow bands is that the light level will decrease and 
there is a risk that intensity contrast will be lost. But a narrow band-pass filter can also 
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maximize the collection of specific signal compared to autofluorescence, resulting in a 
better signal to noise value. 
The number of probes that simultaneously can be monitored depends of the number of 
fluorochromes that can be separated based on wavelength. When a high number of 
fluorophores are used, special attention has to be paid to the spectras, especially the 
emission spectras, to avoid crosstalk between fluorophores. Below is an example how 
emission and excitation filters can be configured, with minimal cross-talk, when using 
four different fluorophores (figure 8). 
 
Figure 8. Absorption- and emission spectra from four different fluorophores (FITC, CY3, Texas Red and 
CY5). In multichannel systems, the excitation- and emission filters spectral bandwidths must be selected 
to optimize collection of the desired fluorescent signal, and at the same time avoid channel cross talk. The 
blue rectangles show optimal settings for excitation and emission filters. 
Instead of separating the fluorophores with narrow filters multichannel unmixing is an 
approach. Spectral unmixing is a function that mathematically removes the crosstalk 
between fluorescent dyes in the digital image (Mansfield, Hoyt et al. 2008). 
6.2.3 Illumination 
Mercury lamps, chosen for their brightness, are the most common light sources used in 
fluorescence microscopy. The spectrum of this light is not continuous; the light output 
is concentrated to a few narrow bands. Choosing filters should be matched to get best 
light possible for each fluorophore. Another illumination source is the xenon arc lamp 
which has a more continuous spectra but is not as bright as a mercury lamp. 
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A common problem in the microscope setting is uneven illumination due to that the 
lamp is not aligned in a correct way. To avoid this liquid light guides can be used 
resulting in uniform illumination in the microscope field. 
6.2.4 Cameras for Digital Microscopy 
The images in fluorescence microscopy are usually acquired with a charged coupled 
device (CCD) camera. The CCD is composed of a large matrix of photosensitive 
elements, pixels, which simultaneously capture an image. The light intensity, i.e. the 
number of photons, for each pixel will be stored as an electronic charge and converted 
to an analogue voltage. This voltage is then converted to a numerical value and stored 
in the computer‟s image file. The most important property of the CCD is its sensitivity 
to detect photons. For weak fluorescence it is important that the CCD can generate 
electric charge from incident photons. The image resolution of the CCD is directly 
proportional to the number of pixel elements in the CCD. 
6.3 THREE-DIMENSIONAL MICROSCOPY 
The original image collected determines the extent of what you can analyze. 
Fluorescence images are often blurred with scattered light coming from fluorescent 
emission that have been diffracted, reflected and refracted by out of focus fluorescence 
from the specimen. As a consequence, the image can be difficult to analyze. To 
overcome this problem there are optical and computational methods that can be applied 
to enhance image quality. 
Confocal microscopy (Carlsson and Aslund 1987) is currently the most widely used 
optical sectioning technique for fluorescence imaging. It is based on the principle that 
out of focus information is rejected by the presence of a pinhole in front of the detector 
and the light source. Only the part of the specimen that is in the focal plane of the 
objective is imaged and light collected from outside the focal plane is rejected by the 
pinhole. The size of the pinhole determines the thickness of one acquired plane. Small 
pinhole size gives better z-resolution, but as a consequence the signal intensity is 
decreased. 
An alternative method for optical sectioning that has been developed for wide-field 
illumination is structured illumination microscopy (Wilson, Neil et al. 1998). In this 
method images in three spatial positions of a grid are acquired and an optically 
sectioned imaged is produced. The depth resolution is similar to that achievable with a 
confocal microscope (Weigel, Schild et al. 2009).  
Deconvolution microscopy (Agard, Hiraoka et al. 1989), on the other hand, is a 
computational method for enhancement of image resolution. A deconvolution 
algorithm is used to restore images to an approximation of what the original object 
looks like. 
All these methods improve the images by removing out of focus light by generating an 
“optical section” through the sample. Only the image information that lies entirely 
within the objective‟s depth of field is displayed. 
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Even if a fluorescence microscopy system was to be equipped with perfect lenses, has 
optimal alignment and large N.A. the theoretical optical resolution is still limited to half 
a wave length. However, in the last decade several new techniques have developed that 
break this limits. These have created new possibilities to investigate the structure of the 
cell. Examples of these so called super-resolution techniques are: Structured 
illumination microscopy (SIM), stimulation depletion depletion (STED) and Single 
molecule localization and composition (PALM/STORM). All these techniques are 
reviewed in (Schermelleh, Heintzmann et al. 2010). 
6.4 DIGITAL IMAGE ACQUISITION, PROCESSING AND ANALYSIS 
Manual classification and quantification of fluorescence labeled genes in a FISH image 
is a very tedious and time consuming task. If the probes are labeled in different color 
combinations, as in M-FISH, the task is almost impossible. We have therefore 
developed an image analysis system for detecting, classifying and quantifying FISH 
labeled genes in cell nuclei. A short version of the methodology used to create a 
complete and working FISH analysis program can be summarized in the following 
steps: 
Sample preparation and molecular hybridization: Good sample preparations are 
essential in achieving good images. In order to generate a strong and specific gene 
signal in the FISH image all steps in sample preparation and molecular hybridization 
have to be optimized. Equally essential is reducing the background noise caused by 
unspecific probe binding and auto fluorescence. 
Image acquisition: The image acquisition is a very important step in the process. 
Images of low quality will have a negative effect on the image analysis. There are 
several factors that influence the quality of the final image. One of these factors is the 
choice of objective. Another one is the choice of filters, to avoid cross-talk between 
different color channels. Furthermore, the image stack acquired has to be large enough 
to cover the entire cell nucleus, and the optical sections have to be thin enough not to 
miss signals. 
Pre-processing: The image has to go through some pre-preparations before analysis 
can begin. This includes removal of dark current from the CCD camera, removal of 
noise and normalization of signal intensities. 
Segmentation I: To able to study the number of signals in each individual cell nucleus, 
the nuclei of interest must be separated from the surrounding nuclei in the image. This 
type of cell segmentation is done semi-automatically in the DAPI (4',6-diamidino-2-
phenylindole) channel. DAPI is a fluorescent stain that binds strongly to DNA and is 
used to counter stain the nuclei. 
Segmentation II: Each labeled chromosomal region will appear as dots in the FISH 
image. Each dot in the nuclei will automatically be extracted. 
Feature extraction: As discussed previously one common artifact in FISH images 
comes from binding of probe to repetitive sequences and this unspecific binding results 
as false dots in the FISH-image. The false dots have to be recognized and removed 
from the image. 
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Figure 9. Schematic image of the image analysis, including segmentation of the nuclei, preprocessing and 
dot detection. In the analyzed M-FISH imaged six genes where labeled in different color combinations 
(Green, orange, red, green/orange, green/red and orange/red) and hybridized to a paraffin section. 
 25 
 
7 AIMS OF THIS THESIS 
The overall aim of this thesis was to study genome rearrangements in breast cancer and 
their relation to tumor progression and risk for metastasis. 
More specifically the aims were: 
 To identify chromosomal alterations and their spatial organization in the cell 
nucleus 
 To study clonal evolution during tumor development and the genetic 
heterogeneity in tumor populations 
 To develop a method to analyze chromosomal translocations in interphase 
chromatin in paraffin embedded tissues 
 To study the translocation between chromosome 1 and 16 in invasive 
carcinoma and DCIS. 
 To study the relationship between genomic alterations, gene expression 
subtypes and clinical data. 
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8 RESULTS AND DISCUSSION 
Paper I 
The introduction of the high resolution aCGH techniques, such as ROMA, has made it 
possible to study recurrent aberrations at a much higher resolution than before. In this 
study we used two methods to study genomic aberrations of breast cancer with high 
resolution: ROMA, which is an aCGH method and interphase M-FISH. Using a 
combination of these two methods we could identify genes and chromosomal regions 
that displayed aberrations as gains or losses and study the quantitative genetic 
imbalances in relation to the progression of the tumors. We especially focused on the 
metastatic process. This was done in detail by examining high resolution data from 243 
breast tumors from two separate studies for which detailed clinical data is available.  
Figure 10. Major types of tumor genomic profiles. Segmentation profiles for individual tumors 
representing each category: (A) simplex; (B) complex type I or sawtooth; (C) complex type II or 
firestorm. The y-axis displays the geometric mean value of two experiments on a log scale Chromosomes 
1-22 plus X and Y are displayed in order from left to right according to probe position. 
By visual inspection of the ROMA profiles, which give information about genomic 
changes of the entire cell population of the tumor, we classified the profiles in to three 
different patterns (Figure 10): The first pattern has broad segments of duplications and 
deletions of whole chromosomes or chromosome arms, and was referred to as 
“simplex”. The second pattern is characterized by many narrow segments of 
duplications and deletions, affecting more or less all of the chromosomes, and we 
called this pattern complex 1 or “sawtooth”. The third pattern is similar to the simplex 
pattern, except that the ROMA profile has one or more localized region consisting of a 
collection of narrow peaks of amplifications. We call this pattern complex 2 or 
“firestorm”. 
The simplex group was shown to be associated with good outcome and is typical of 
low-grade cancers, frequently displaying coexisting 1q gain and 16q losses. On the 
other hand the complex patterns highly correlate with aggressive disease and poor 
survival. In the simplex tumors some specific chromosome arm gains and losses are 
more frequent than others, and a subset of these seems to appear in almost every 
simplex tumor. The aberrations in this subset are duplications of 1q, 8q, and 16p and 
deletions of 8p, 16q and 22q. 
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For a more detailed analysis on the individual cell level we used interphase FISH to 
validate the segmented ROMA profiles. For this BAC clones or Oligonucleotide Probes 
representing different loci, both peaks and valleys in the segmented ROMA profiles, 
were selected as probes for FISH. Studying tumors with the firestorm pattern clearly 
indicated that amplifications of neighboring peaks on a chromosome occur in the same 
cell and that they do not arise from clonal subpopulations (Figure 11B). This is 
something the population based ROMA method could not depict. Co-localization of 
amplifications from the same chromosome arm also indicates that the amplifications 
occur on the same chromosome arm (Figure 11C). 
Firestorms regions could be seen at least once on most chromosomes in the tumors of 
the firestorm tumor set. Some chromosome arms, however, seem to undergo this 
process more often. Chromosome 6, 8, 11, 17 and 20 are frequently affected, and of 
these 11q and 17q are affected the most. 
 
Figure 11. Validation of peaks and valleys in ROMA profiles by interphase FISH. (A) Expanded ROMA 
profile of a firestorm on chromosome 8 in a diploid tumor. The graph shows the normalized raw data 
(gray) and segmented profile (red) along with the genes for which the probes shown in the FISH images 
were constructed. Several distinct conditions are exemplified in the images. Tight clusters of multiple 
copies corresponding to ROMA peaks are also shown in the FISH images for CKS1A, MYC, TPD52, 
and the uncharacterized ORF AK096200. Note that the FISH signals corresponding to distinct loci cluster 
together irrespective of their distance on the same arm (CKS1A/MYC) or across the centromere 
(BAG4/AK09620) 
Taken together, the profiles described in this study can be useful for evaluating the 
relationship between “firestorms” and the locations of candidate oncogenes and tumor 
suppressors in the genome. It can also help us identify genes that drive cancer 
 28 
 
progression and solve the complex genetic pathway that underlies the process of tumor 
metastasis.  
We have identified about between 50 and 100 chromosomal regions that have been 
found to be amplified or deleted in breast cancer. The fact that the number of 
chromosomal regions that are altered in cancer cells is relatively limited enables us to 
study them with FISH. 
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Paper II 
Until recently, most tumor CGH-analyses have been done on samples on a large 
number of tumor cells, a method that hides individual variation among cells and can 
cause misclassification of cancer. We developed a new technique, sector ploidy 
profiling (SPP), which allows us to sort and segregate single cells and amplify portions 
of their genome for analysis. This technique made it possible to utilize the 
heterogeneity in breast cancers and to examine the genomic evolution of the tumors, by 
studying individual cells within a tumor.  
In this paper we combined SPP with M-FISH to study the clonal composition of a 
tumor and tumor progression. Our hypothesis was that some solid tumors contain 
subpopulations with variations in their genomes. To test this assumption, four high 
grade tumors were dissected into four sectors, and ROMA profiles were rendered from 
DNA isolated from each sector. Two of the tumors contained minimal variation in their 
genomic copy number profiles in all four sectors, whereas the other two tumors had a 
large degree of genomic variation in the different sectors. The two tumors that 
displayed a stable genome profile are referred as „monogenomic‟ because it consists of 
one single tumor profile. The other two tumors, that showed diverse genomic profile 
between the different sectors, are referred to as „polygenomic‟, since there are multiple 
tumor subpopulations present. These results indicate that tumor heterogeneity is quite 
common. However, one problem with this approach is that the proportion of normal 
and tumor cells can vary greatly between different tumor sectors, and this may 
confound the interpretation of the copy number profiles. To avoid this problem a 
method to separate subpopulations within the tumor before ROMA analysis was 
developed. Using this novel method help us to further improve the genetic 
classification of tumors. 
To be able to study the number of populations and to get a clearer picture of the 
subpopulations and their clonal relationship the method SPP was developed. This 
method separates tumor subpopulations by region and ploidy and mitigates the mixing 
effect of normal and tumor cells. 
To perform SPP, a tumor is macro dissected into 12 sectors. From six of these nuclei 
are isolated and stained with DAPI for flow sorting. The sorting of cells by FACS is 
gated according to differences in total genomic DNA content. DNA from each peak is 
then prepared and analyzed using ROMA. The remaining 6 sections were saved for 
interphase M-FISH. 
After performing SPP on 16 tumors we could still classify the tumors into two groups: 
(i) monogenomic (7 tumors) and (ii) polygenomic (9 tumors). However, using the SPP 
approach we were, in addition to the grouping, able to identify many subpopulation-
specific chromosome markers. These markers are useful for studying tumor progression 
particularly when elucidating the genetic evolution in the tumors. By assuming that 
genomic complexity increase during tumor progression, we sorted the copy number 
profiles by increasing number of chromosomal breakpoints and identified genetic 
events that occurred during tumor evolution. 
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To explore the spatial organization of the subpopulations of these tumors, we used 
interphase FISH on tissue sections to study single cells. In one polygenomic tumor we 
identified a massive amplification in two of the six sectors by using SPP. The 
discovered area is a 3.6 mb amplicon containing the KRAS oncogene and several other 
genes. To study this area of the genome in detail we generated a BAC probe for FISH, 
and hybridized it to all tissue sections analogous to the sectors and as expected we 
identified the amplification in sectors showing amplification in the ROMA-profiles 
(Figure 12D). Furthermore, in one sector we observed isolated cells with amplification 
for KRAS, which was not detected by the ROMA (Figure 12C). This result shows that 
tumor subpopulations can be anatomically segregated into different regions of a tumor. 
We could also, by doing M-FISH, show that genetically different tumor subpopulations 
and normal diploid cells can be intermixed within tissues. 
Comparing different subpopulations from different areas in a tumor enabled us to infer 
pathways of cancer progression and the organization of tumor growth. 
 
Figure 12. Regional amplification of the KRAS locus. (A) Ideogram showing the cytobands and location 
of the KRAS FISH probe. (B-D) Topography of each tumor sector (left), ROMA profile (middle) and 
FISH-image (right). (B) Sector 1 show two or three copies of the KRAS locus in the stromal and tumor 
cells. This corresponds well to the ROMA-profile. (C) In sector 4 a majority of the tumor and stromal 
cells has two or three copies, which corresponds well to the ROMA-profile. However one tumor cell 
shows a massive amplification. (D) Sector 5 show numerous tumor cells with massive amplification, this 
correspond well to the ROMA-profile.  
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Paper III 
Inspired by the three different patterns of segmented genome profiles, “simplex”, 
“firestorm” and “sawtooth” presented in paper I, we developed an objective estimate of 
genomic alterations in aCGH data. Further we investigate the relationship between 
genomic alterations, molecular expression subtypes, structural rearrangements and 
clinical data. 
Two new algorithms to objectively estimate genomic complexity were developed using 
segmented aCGH data: 1) whole-arm aberration index (WAAI) and 2) complex arm 
aberration index (CAAI). The WAAI score was used to capture events on whole 
chromosome arms. CAAI on the other hand was used to recognize regions with 
structural complexity. We defined whole arm gains as WAAI ≥ 0.8 and whole arm 
losses as WAAI≤-0.8. Areas of complex rearrangements were found by selecting 
chromosome arms with a CAAI ≥0.5. 
Luminal A tumors, dominated by ER-positive tumors, have few chromosomal 
alterations, often with gain of 1q and loss of 16q. Basal-like tumors, on the other hand, 
have many alterations affecting most of the chromosomes. Loss on 5q and gain on 10p 
have been suggested as a specific Basal-like variation (Bergamaschi, Kim et al. 2006). 
On the basis of this, and by using the WAAI cutoffs described above, we defined 4 
subgroups based on genomic architecture: (A) 1q gain and/or 16q loss, (B) regional loss 
of 5q and/or regional gain of 10p, (AB) both A and B and (C) those with neither. These 
subgroups showed distinct differences with respect to whole arm losses and gains. The 
groups were further characterized by dividing them into CAAI subgroups. CAAI<0.5 
for all arms were denoted A1, B1, AB1 and C1 and CAAI ≥0.5 for at least one arm 
were denoted A2, B2, AB2 and C2. 
Comparison of the expression based classification with this novel aCGH based 
grouping showed that the A group was enriched in Luminal A tumors and the B group 
in Basal-like tumors. The A and B groups displayed different types of chromosomal 
aberrations. In the A group, gains and losses of whole chromosomes and chromosome 
arms dominated, whereas B tumors had more genomic loss and more regional 
aberrations. The mortality in the B group was twice as high as it was in the type A 
group independent of lymph node status, tumor size, histological grade and treatment. 
Tumors of type A were selected due to having gain of 1q and/or loss of 16q, and these 
events were frequently concurrent. An unbalanced translocation between chromosomes 
1 and 16 has previously been reported (Tsarouha, Pandis et al. 1999). We believe that 
the gain of 1q and loss of 16q we observe in the A group is a consequence of this 
translocation. This hypothesis was confirmed when we showed this translocation by M-
FISH in one of the tumors in group A. Tumors with this typical 1q gain, 16q loss 
pattern are further studied in paper IV. 
Clinical follow up data were available for a majority of the patients, and the CAAI 
score was shown to be an independent prognostic factor. In patients with tumors with 
high CAAI score the risk of breast cancer related death was twice as high as in patients 
with tumors with a low CAAI score. This was independent of lymph node status, tumor 
size, histological grade and WAAI class.  
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Paper IV. 
In papers I and III we concluded by observing ROMA profiles, that there is a group of 
low malignant tumors that often have a duplication of 1q simultaneously with a 
deletion of 16q. This aberration has previously been detected by others and is 
considered to be one of the earliest changes in carcinogenesis of the breast. Based on 
this, we assumed that a gain on 1q together with loss of 16q reflects the translocation 
t(1;16) which have previously been described as an common translocation in breast 
cancer. 
By combining ROMA with M-FISH it is possibly to identify specific translocations in 
interphase chromatin in clinical samples. As a first approach we identified the 
suspected breakpoints in frequency plots generated from 140 ROMA profiles. In the 
frequency plots we could clearly see that most chromosomal breakpoints were close or 
within the centromere on both chromosome 1 (1p12-1q12) and chromosome 16 
(16p11.2-16p11.1). 
Chromosomal regions specific for each side of the breakpoints were defined and BACs 
were selected from each chromosomal region. To be able to visualize suspected 
translocations, which would show up as co-localization of signals deriving from 1q and 
16p, hybridization probes from each side of the breakpoints were selected and labeled 
in different colors. By this approach we were able to identify translocations in tumor 
samples from paraffin sections (Figure 13). In paper I it was suggested that the gain of 
1q together with loss of 16q is an early event in cancer development. We therefore used 
this method on tumor sections with ductal cancer in situ (DCIS) and could identify the 
tranlocation t(1;16). 
In paraffin sections, some of the cells are cut as part of the sample preparation process. 
As a consequence of this parts of the cell nucleus can be lost and the M-FISH pattern 
specific for translocation cannot be seen in all cells. To determine if an 
area/subpopulation have cells with translocations or not we made an assumption that 
cells where 16p and 16q always co-exist are normal cells and where 16q have been lost 
have a translocation. We scored all signals from 16p and 16q in the area and calculated 
the 16p/16q ratio as an estimate of the frequency of translocation t(1q;16p). By 
analyzing the distribution of cells, with this approach, in a DCIS area we observed a 
diversity of cells, where some cells had translocation pattern and others that did not 
(Figure 14). This suggests that intraductal proliferation leading to DCIS precedes the 
translocation t(1;16). 
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Figure 13. The image shows one normal copy of chromosome 1 (purple (1p) -green (1q)) and one normal 
copy of chromosome 16 (red (16p) – orange (16q)). In the translocation t(1q;16p) the green probe (1q) 
has been translocated close to the red probe (16p). 
 
 
Figure 14. Cells in a DCIS area divided into two groups depending on the ratio 16p/16q. “Normal” cells 
with intact chromosome 16 were labeled green and cells with translocation pattern (loss of 16q) were 
labeled red. We can see that the two populations are fairly mixed in the area.   
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9 GENERAL CONCLUSIONS 
Based on the findings in this thesis the following conclusions can be made: 
 Three characteristic patterns of genomic rearrangements were identified, and 
found to be associated with tumor progression and risk for metastasis. 
 Clonal genomic heterogeneity was found to be common in breast cancer. The 
clonal subpopulations may be anatomically separated or intermixed. A better 
understanding of the order of genomic events during tumor development could 
be obtained. 
 By combining ROMA with M-FISH it became possible to study specific 
translocations in interphase chromatin in clinical samples. The specific 
translocation t(1;16) could be found in both invasive breast cancer and DCIS. 
 An objective mathematical analysis of the genomic rearrangements can be used 
to define genome expression subtypes of breast cancer. Genomic alteration such 
as complex rearrangements measured objectively can be used as a prognostic 
tool in breast cancer. 
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